SLAM Bio is an oncology biotech company developing a platform of first-in-class antibodies and bispecifics against signaling lymphocytic activation molecule (SLAM) protein family. This is an intriguing biotech investment opportunity, one that holds potential to significantly impact the lives of patients with life threatening cancers, including AML, MDS and CTCL. We have selected our Drug Candidate (DC) and will be in the clinic end of next year. Guiding our biotech is a seasoned and proven oncology leadership team with a track record of high multiple exits. This pioneering work is founded on research originating from City of Hope (led by Dr. Steven Rosen).